Use of Statins and the Risk of Incident Diabetes: A Retrospective Cohort Study

Olotu, Busuyi; Shepherd, Marvin D.; Novak, Suzanne; Lawson, Kenneth A.; Wilson, James P.; Richards, Katherine; Rasu, Rafia S.

doi:10.1007/s40256-016-0176-1

Cited by 18 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Large scale randomized controlled trials have demonstrated that statin treatment can induce hyperglycemia and augments the risk for diabetes [15,16]. For atorvastatin and simvastatin, it has been reported that they increase the risk for diabetes in a dose-dependent manner [17,18]. In populations with high risk for type 2 diabetes, approximately 30% of the patients treated with statins developed diabetes [19,20].…”

Section: Introductionmentioning

confidence: 99%

Simvastatin Impairs Glucose Homeostasis in Mice Depending on PGC-1α Skeletal Muscle Expression

et al. 2020

View full text Add to dashboard Cite

Several studies showed an increased risk for diabetes with statin treatment. PGC-1α is an important regulator of muscle energy metabolism and mitochondrial biogenesis. Since statins impair skeletal muscle PGC-1α expression and reduced PGC-1α expression has been observed in diabetic patients, we investigated the possibility that skeletal muscle PGC1α expression influences the effect of simvastatin on muscle glucose metabolism. Mice with muscle PGC-1α knockout (KO) or PGC-1α overexpression (OE), and wild-type (WT) mice were investigated. Mice were treated orally for 3 weeks with simvastatin (5 mg/kg/day) and investigated by intraperitoneal glucose tolerance (iGTT), in vivo skeletal muscle glucose uptake, muscle glycogen content, and Glut4 and hexokinase mRNA and protein expression. Simvastatin impaired glucose metabolism in WT mice, as manifested by increased glucose blood concentrations during the iGTT, decreased skeletal muscle glucose uptake and glycogen stores. KO mice showed impaired glucose homeostasis with increased blood glucose concentrations during the iGTT already without simvastatin treatment and simvastatin induced a decrease in skeletal muscle glucose uptake. In OE mice, simvastatin treatment increased blood glucose and insulin concentrations during the iGTT, and increased skeletal muscle glucose uptake, glycogen stores, and Glut4 and hexokinase protein expression. In conclusion, simvastatin impaired skeletal muscle insulin sensitivity in WT mice, while KO mice exhibited impaired skeletal muscle insulin sensitivity already in the absence of simvastatin. In OE mice, simvastatin augmented muscular glucose uptake but impaired whole-body insulin sensitivity. Thus, simvastatin affected glucose homeostasis depending on PGC-1α expression.

show abstract

Section: Introductionmentioning

confidence: 99%

Simvastatin Impairs Glucose Homeostasis in Mice Depending on PGC-1α Skeletal Muscle Expression

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The results of some other studies show the effect of using statin, on increasing the risk of diabetes (14,13) and increased HbA1c in patients with and without diabetes (15,16). In another study, use of statin in patients with type 1 diabetes was accompanied by increased HbA1c in these patients.…”

Section: Introductionmentioning

confidence: 89%

Investigating the effect of atorvastatin drug on HbA1c in patients with myocardial infarction hospitalized in Farshchian Hospital, Hamadan province, Iran, in 2014-2015 (a before-after study)

2019

View full text Add to dashboard Cite

Use of statins reduces the risk of cardiovascular diseases, however, in some studies, contradicting results about statins especially atorvastatin with the risk of diabetes have been reported. The purpose of the present study, was to investigate the effect of atorvastatin drug on HbA1c in patients with myocardial infarction hospitalized in Farshchian Hospital, Hamadan. 60 patients hospitalized in CCU, who were diagnosed with one type of infarction were included in this clinical trial performed as a before-after study. Demographic data were collected using a questionnaire. Before the study and 6 months after the start of the study, the parameters of lipid profile, HbA1c and GFR were measured. Atorvastatin with a dose of 80mg was given to the patients from the beginning of the study for 6 months. The results were analyzed using SPSS. The average age of the male and female patients was 63.83 and 61.11, respectively, which had an insignificant difference. 42 patients (70%) were male and the rest of them were female. Lipid profile results at the end of the study showed improved averages for the parameters, all of which were statistically significant compared to their values at the start of the study. The mean HbA1c increased from 6.19 to 6.43 (P=0.001), the mean fasting blood sugar increased from 103.66 to 110.51 (P=0.001), and the average glomerular filtration rate (GFR) decreased from 69.84 from the start of the study to 67.43 which was statistically significant (P=0.002). Systolic and diastolic blood pressure at the end of the study decreased compared to the start of the study where in systolic blood pressure, this decrease was significant (p=0.003). Based on the results of this study, although the use of atorvastatin reduces lipids, it may create the risk of hyperglycemia in these patients. However, a certain conclusion requires further studies.

show abstract

“…Recent meta-analyses have revealed a small but statistically significant increase in diabetes, with a number needed to harm of 225 patients (over 4 years) in one study 62 and an incidence rate of 2.2% (2 years) in another. 63 If statins induce diabetes in patients with diseases such as NASH, anticipated benefits could be negated.…”

Section: Potential Risks and Recommended Monitoringmentioning

confidence: 99%

Statins Show Promise Against Progression of Liver Disease

Francis¹,

Forman²

2021

Clinical Liver Disease

View full text Add to dashboard Cite

show abstract

Use of Statins and the Risk of Incident Diabetes: A Retrospective Cohort Study

Abstract: Because the potential for diabetogenicity differs among different statin types, healthcare professionals should individualize statin therapy by identifying patients who would benefit more from less diabetogenic statin types.

Cited by 18 publications

References 35 publications

Simvastatin Impairs Glucose Homeostasis in Mice Depending on PGC-1α Skeletal Muscle Expression

Simvastatin Impairs Glucose Homeostasis in Mice Depending on PGC-1α Skeletal Muscle Expression

Investigating the effect of atorvastatin drug on HbA1c in patients with myocardial infarction hospitalized in Farshchian Hospital, Hamadan province, Iran, in 2014-2015 (a before-after study)

Statins Show Promise Against Progression of Liver Disease

Contact Info

Product

Resources

About